Literature DB >> 3174741

Chronic stress increases the binding of the A1 adenosine receptor agonist, [3H]cyclohexyladenosine, to rat hypothalamus.

S M Anderson1, J R Leu, G J Kant.   

Abstract

We previously reported an increase in the binding of [3H]cyclohexyladenosine ([3H]CHA) to brain membranes from the hypothalamus of rats sacrificed following three days of chronic stress in an around-the-clock intermittent footshock avoidance/escape paradigm ("sustained performance" stress). Here we report stress-induced increases in [3H]CHA binding to hypothalamic membranes from rats stressed for 14 days in that escape/avoidance paradigm, in rats exposed to repeated restraint (3 hr/day for 10 days) and in rats exposed to four days of "activity-stress." Data from saturation binding experiments indicate that this up-regulation was due to an increase in the apparent number of [3H]CHA binding sites without change in affinity for [3H]CHA. Neither restraint for one three-hr period nor one 15-min exposure to intermittent footshock resulted in significant changes in [3H]CHA binding to hypothalamic membranes. Our present data demonstrate small but consistent increases in the number of [3H]CHA binding sites in hypothalamic membranes from rats stressed in several different chronic stress models but no change by acute stress.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3174741

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  2 in total

1.  Adaptive protection of the heart and stabilization of myocardial structures.

Authors:  F Z Meerson; A V Zamotrinsky
Journal:  Basic Res Cardiol       Date:  1991 Mar-Apr       Impact factor: 17.165

2.  Restraint stress fails to modulate cutaneous hypersensitivity responses in mice lacking the adenosine A1 receptor.

Authors:  Stephen J Oliver; Sneha Mathew; Tuère F Wilder; Bruce N Cronstein
Journal:  Purinergic Signal       Date:  2011-02-08       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.